| scholarly article | Q13442814 |
| P50 | author | Urszula Czubek | Q114443042 |
| Pawel Rostoff | Q59393186 | ||
| Grzegorz Gajos | Q59829230 | ||
| Aleksander Siniarski | Q61131598 | ||
| Jaroslaw Zalewski | Q91313097 | ||
| Jadwiga Nessler | Q110726810 | ||
| P2093 | author name string | Rafal Grzybczak | |
| P2860 | cites work | The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts | Q24675155 |
| Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding | Q26829251 | ||
| New insights into the determination of HDL structure by apolipoproteins: Thematic review series: high density lipoprotein structure, function, and metabolism | Q26851804 | ||
| Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction | Q28168881 | ||
| Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2 | Q28188067 | ||
| Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein | Q28206260 | ||
| High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study | Q30450312 | ||
| Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. | Q33804996 | ||
| Platelet hypersensitivity induced by cholesterol incorporation | Q34475652 | ||
| Apolipoprotein A-II, HDL metabolism and atherosclerosis | Q34740994 | ||
| High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies | Q34748074 | ||
| Endothelial and antithrombotic actions of HDL. | Q36500929 | ||
| Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease | Q37286296 | ||
| Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. | Q37786695 | ||
| Molecular physiology of reverse cholesterol transport | Q40526401 | ||
| Global cardiovascular mortality risk in the adult Polish population: prospective assessment of the cohorts studied in multicentre national WOBASZ and WOBASZ Senior studies | Q40543523 | ||
| Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey | Q40838547 | ||
| Functional assessment of HDL: Moving beyond static measures for risk assessment | Q43186286 | ||
| High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial | Q46375288 | ||
| 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. | Q50089557 | ||
| Impact of low level of high-density lipoprotein-cholesterol sampled in overnight fasting state on the clinical outcomes in patients with acute myocardial infarction (difference between ST-segment and non-ST-segment-elevation myocardial infarction). | Q51315519 | ||
| Native high-density lipoproteins inhibit platelet activation via scavenger receptor BI: role of negatively charged phospholipids. | Q54613595 | ||
| 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation | Q57621035 | ||
| The impact of high density lipoprotein on oxidant-antioxidant balance in healthy elderly subjects | Q61631468 | ||
| High density lipoproteins enhance the Na+/H+ antiport in human platelets | Q71352801 | ||
| Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) | Q73419520 | ||
| ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome | Q81445965 | ||
| Procoagulant activities of plasma factor VIIc and factor Xc are positively and independently associated with concentrations of the high-density lipoprotein apolipoprotein, apo A-II | Q81920481 | ||
| Influence of high-density lipoprotein and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy | Q82079392 | ||
| Suboptimal response to clopidogrel and the effect of prasugrel in acute coronary syndromes | Q83782548 | ||
| Smoking, atherothrombosis and clopidogrel | Q84300365 | ||
| Early determination of clopidogrel responsiveness by platelet reactivity indexidentifies patients at risk for cardiovascular events after myocardial infarction | Q84309486 | ||
| Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes | Q84974492 | ||
| Obesity and antiplatelet effects of acetylsalicylic acid and clopidogrel in patients with stable angina pectoris after percutaneous coronary intervention | Q85852116 | ||
| High on-treatment platelet reactivity--definition and measurement | Q86174316 | ||
| Changes in the prevalence, treatment, and control of hypercholesterolemia and other dyslipidemias over 10 years in Poland: the WOBASZ study | Q87989349 | ||
| P433 | issue | 6 | |
| P921 | main subject | lipoprotein | Q28350 |
| P304 | page(s) | 374-381 | |
| P577 | publication date | 2018-06-01 | |
| P1433 | published in | Anatolian Journal of Cardiology | Q15716765 |
| P1476 | title | Association of serum levels of lipoprotein A-I and lipoprotein A-I/A-II with high on-treatment platelet reactivity in patients with ST-segment elevation myocardial infarction. | |
| P478 | volume | 19 |
Search more.